A TRPV2 interactome-based signature for prognosis in glioblastoma patients

Doñate-Macián, Pau; Gómez, Antonio; Dégano, Irene R.; Perálvarez Marín, Alex

doi:http://dx.doi.org/10.18632/oncotarget.24843

A TRPV2 interactome-based signature for prognosis in glioblastoma patients

License

Citation

Doñate-Macián P, Gómez A, Dégano IR, Perálvarez-Marín A. A TRPV2 interactome-based signature for prognosis in glioblastoma patients. Oncotarget. 2018 Apr 6;9(26):18400-9. DOI: 10.18632/oncotarget.24843

Abstract

Proteomics aids to the discovery and expansion of protein-protein interaction networks, which are key to understand molecular mechanisms in physiology and physiopathology, but also to infer protein function in a guilt-by-association fashion. In this study we use a systematic protein-protein interaction membrane yeast two-hybrid method to expand the interactome of TRPV2, a cation channel related to nervous system development. After validation of the interactome in silico, we define a TRPV2-interactome signature combining proteomics with the available physio-pathological data in Disgenet to find interactome-disease associations, highlighting nervous system disorders and neoplasms. The TRPV2-interactome signature against available experimental data is capable of discriminating overall risk in glioblastoma multiforme prognosis, progression, recurrence, and chemotherapy resistance. Beyond the impact on glioblastoma physiopathology, this study shows that combining systematic proteomics with in silico methods and available experimental data is key to open new perspectives to define novel biomarkers for diagnosis, prognosis and therapeutics in disease.